Tedford; Clark E.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Tedford; Clark E..The latest application filed is for "stable preservative-free mydriatic and anti-inflammatory solutions for injection".

Company Profile

13.21.43

Tedford; Clark E. - Poulsbo WA
Tedford; Clark E - Poulsbo WA
Tedford, Clark E - Russell OH
Tedford, Clark E. - South Russell OH
Tedford; Clark E. - South Russel OH
Tedford; Clark E. - S. Russell OH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Stable Preservative-free Mydriatic And Anti-inflammatory Solutions For Injection App 20220175726 - Demopulos; Gregory A. ; et al.	2022-06-09
Multi-wavelength Phototherapy Devices, Systems, And Methods For The Non-invasive Treatment Of Damaged Or Diseased Tissue App 20210315736 - Tedford; Clark E ; et al.	2021-10-14
Methods For Treating Ocular Disease App 20210178178 - TEDFORD; Clark E.	2021-06-17
Methods For Preventing And Treating Ocular Disease App 20210059858 - Eells; Janis T. ; et al.	2021-03-04
Compositions For Inhibiting Masp-2 Dependent Complement Activation App 20210054099 - Dudler; Thomas ; et al.	2021-02-25
Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation App 20210040229 - Schwaeble; Hans-Wilhelm ; et al.	2021-02-11
Multi-wavelength phototherapy systems and methods for the treatment of damaged or diseased tissue Grant 10,881,550 - Tedford , et al. January 5, 2	2021-01-05
Devices And Methods For Non-invasive Multi-wavelength Photobiomodulation For Ocular Treatments App 20200315844 - Tedford; Clark E. ; et al.	2020-10-08
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20200190215 - Schwaeble; Hans-Wilhelm ; et al.	2020-06-18
Compositions for inhibiting MASP-2 dependent complement activation Grant 10,683,367 - Dudler , et al.	2020-06-16
Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation App 20200157245 - Schwaeble; Hans-Wilhelm ; et al.	2020-05-21
Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments Grant 10,596,037 - Tedford , et al.	2020-03-24
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20200040104 - Demopulos; Gregory A. ; et al.	2020-02-06
Devices And Methods For Non-invasive Multi-wavelength Photobiomodulation For Ocular Treatments App 20190142636 - Tedford; Clark E. ; et al.	2019-05-16
Compositions for Inhibiting MASP-2 Dependent Complement Activation App 20190119402 - Dudler; Thomas ; et al.	2019-04-25
Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments Grant 10,219,944 - Tedford , et al.	2019-03-05
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20180291111 - Demopulos; Gregory A. ; et al.	2018-10-11
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation App 20180291112 - Schwaeble; Hans-Wilhelm ; et al.	2018-10-11
Compositions for inhibiting MASP-2 dependent complement activation Grant 10,047,165 - Dudler , et al. August 14, 2	2018-08-14
Stable Preservative-free Mydriatic And Anti-inflammatory Solutions For Injection App 20180085349 - Demopulos; Gregory A. ; et al.	2018-03-29
Stable preservative-free mydriatic and anti-inflammatory solutions for injection Grant 9,855,246 - Demopulos , et al. January 2, 2	2018-01-02
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation App 20170233494 - Schwaeble; Hans-Wilhelm ; et al.	2017-08-17
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20170233493 - Schwaeble; Hans-Wilhelm ; et al.	2017-08-17
Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection App 20170196838 - Demopulos; Gregory A. ; et al.	2017-07-13
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20170166660 - Schwaeble; Hans-Wilhelm ; et al.	2017-06-15
Compositions For Inhibiting Masp-2 Dependent Complement Activation App 20170088632 - Dudler; Thomas ; et al.	2017-03-30
Stable preservative-free mydriatic and anti-inflammatory solutions for injection Grant 9,486,406 - Demopulos , et al. November 8, 2	2016-11-08
Multi-wavelength Phototherapy Systems And Methods For The Treatment Of Damaged Or Diseased Tissue App 20160317833 - Tedford; Clark E ; et al.	2016-11-03
Compositions for inhibiting MASP-2 dependent complement activation Grant 9,475,885 - Dudler , et al. October 25, 2	2016-10-25
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20160272727 - Demopulos; Gregory A. ; et al.	2016-09-22
Devices And Methods For Non-invasive Multi-wavelength Photobiomodulation For Ocular Treatments App 20160067086 - Tedford; Clark E. ; et al.	2016-03-10
Wearable Devices And Methods For Multi-wavelength Photobiomodulation For Ocular Treatments App 20160067087 - Tedford; Clark E ; et al.	2016-03-10
Compositions For Inhibiting Masp-2 Dependent Complement Activation App 20160002349 - Dudler; Thomas ; et al.	2016-01-07
Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection App 20150342928 - Demopulos; Gregory A. ; et al.	2015-12-03
Stable preservative-free mydriatic and anti-inflammatory solutions for injection Grant 9,066,856 - Demopulos , et al. June 30, 2	2015-06-30
Compositions for inhibiting MASP-2 dependent complement activation Grant 9,011,860 - Dudler , et al. April 21, 2	2015-04-21
Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation App 20150064176 - Schwaeble; Hans-Wilhelm ; et al.	2015-03-05
Methods for treating conditions associated with MASP-2 dependent complement activation Grant 8,840,893 - Schwaeble , et al. September 23, 2	2014-09-23
Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection App 20140235691 - Demopulos; Gregory A. ; et al.	2014-08-21
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation App 20140205598 - Schwaeble; Hans-Wilhelm ; et al.	2014-07-24
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20140056873 - Schwaeble; Hans-Wilhelm ; et al.	2014-02-27
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation Grant 8,652,477 - Schwaeble , et al. February 18, 2	2014-02-18
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation App 20130266559 - Demopulos; Gregory A. ; et al.	2013-10-10
Compositions For Inhibiting Masp-2 Dependent Complement Activation App 20120282263 - Dudler; Thomas ; et al.	2012-11-08
Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation App 20110311549 - Schwaeble; Hans-Wilhelm ; et al.	2011-12-22
Methods For Treating Disseminated Intravascular Coagulation By Inhibiting Masp-2 Dependent Complement Activation App 20110091450 - Schwaeble; Hans-Wilhelm ; et al.	2011-04-21
Methods for treating conditions associated with MASP-2 dependent complement activation Grant 7,919,094 - Schwaeble , et al. April 5, 2	2011-04-05
Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation App 20110020337 - Schwaeble; Hans-Wilhelm ; et al.	2011-01-27
Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation App 20100074899 - Schwaeble; Hans-Wilhelm ; et al.	2010-03-25
Methods for treating conditions associated with MASP-2 dependent complement activation App 20070172483 - Schwaeble; Hans-Wilhelm ; et al.	2007-07-26
Novel serotonin receptor ligands and their uses thereof App 20060035883 - Tedford; Clark E. ; et al.	2006-02-16
Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists App 20060035889 - Tedford; Clark E. ; et al.	2006-02-16
Methods for treating conditions associated with lectin-dependent complement activation App 20060018896 - Schwaeble; Hans-Wilhelm ; et al.	2006-01-26
Methods for treating conditions associated with MASP-2 dependent complement activation App 20060002937 - Schwaeble; Hans-Wilhelm ; et al.	2006-01-05
Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity App 20040006120 - Yates, Stephen L ; et al.	2004-01-08
Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity App 20030069295 - Yates, Stephen L. ; et al.	2003-04-10
1H-4(5)-substituted imidazole derivatives Grant 6,448,282 - Phillips , et al. September 10, 2	2002-09-10
1H-4(5)-substituted imidazole derivatives Grant 6,166,060 - Phillips , et al. December 26, 2	2000-12-26
2-(1H-4(5)-imidazoyl) cyclopropyl compounds Grant 5,990,317 - Phillips , et al. November 23, 1	1999-11-23
2-(4-imidazoyl) cyclopropyl derivatives Grant 5,652,258 - Phillips , et al. July 29, 1	1997-07-29
Histamine H.sub.3 -receptor antagonists and therapeutic uses thereof Grant 5,486,526 - Durant , et al. January 23, 1	1996-01-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.